A Phase III Single-center, Randomized, Double-Blinded, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of Emodepside Compared to Multiple Doses of Mebendazole in Adolescent and Adult Participants With Soil-transmitted Helminthiasis

This study aims to assess the efficacy and safety of emodepside compared to mebendazole in adults and adolescents infected with T. trichiura, either as single infection or co-infections with hookworm and/or A. lumbricoides.

开始日期2026-04-01

申办/合作机构

Swiss Tropical & Public Health Institute

[+3]

NCT07258173

/ Not yet recruiting临床2期IIT

Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita: a Phase II, Randomized, Double Blind, Controlled Trial

The purpose of this clinical trial is to compare the efficacy and safety of emodepside, with the standard treatment, albendazole, in adolescents (12 years and older) and adults infected with Trichuris incognita.

开始日期2026-01-15

申办/合作机构

Swiss Tropical & Public Health Institute

[+2]

NCT06736691

/ Enrolling by invitation临床3期IIT

A Phase III Single-center, Randomized, Double-blinded, Parallel-group, Active-controlled Study to Evaluate the Efficacy and Safety of a Single Dose of Emodepside Compared to Multiple Doses of Mebendazole in Adolescent and Adult Participants With Soil-transmitted Helminthiasis

开始日期2025-11-25

申办/合作机构

Swiss Tropical & Public Health Institute

[+3]

100 项与依莫赛普相关的临床结果

登录后查看更多信息

100 项与依莫赛普相关的转化医学

登录后查看更多信息

100 项与依莫赛普相关的专利（医药）

登录后查看更多信息

173

项与依莫赛普相关的文献（医药）

2026-02-01·JOURNAL OF PHARMACEUTICAL SCIENCES

Can an absorptive sink improve the predictivity of biomimetic two-stage dissolution testing? Comparative IVIVC of various formulations of the poorly soluble drug emodepside

Article

作者: Karl, Maximilian ; Feldmueller, Maximilian ; Lillotte, Tim ; Lynnerup, Jakob Tobias ; Bauer-Brandl, Annette ; Brandl, Martin ; Oversohl, Dennis ; Münster, Uwe

Drug release from four different formulations of the poorly soluble drug emodepside was determined in absence and presence of an absorptive sink (absorptive compartment separated by a barrier) by analyzing both molecularly dissolved and apparently dissolved drug concentrations in parallel. To this end, microdialysis and in situ 2nd derivative UV spectroscopy were employed. Two dose strengths each were investigated of crystalline conventional release tablets, pH-dependent hydroxypropyl methylcellulose acetate succinate-based amorphous solid dispersion (ASD) tablets, pH-independent polyvinylpyrrolidone vinyl acetate ASD tablets, and a polyethylene glycol 400 (PEG₄₀₀)-based oral solution. The presence of the absorptive sink did significantly increase the (molecularly dissolved) supersaturation in the case of the PEG₄₀₀-based oral solution as compared to previously published dissolution data while the supersaturation enhancement caused by the absorptive sink for the other formulations was moderate to marginal. This indicates that, for different formulation types, the dynamic interplay between dissolution, supersaturation, colloid-association, and precipitation is captured better by combined dissolution-permeation. Furthermore, the predictive potential of combined dissolution-permeation testing compared to mere dissolution testing was evaluated. The extent and duration of both molecular and apparent dissolution were compared to human plasma concentration time curves to establish in vitro in vivo correlation (IVIVC). Likewise, the initial flux as well as cumulative amount permeated across the PAMPA barrier of the dissolution-permeation assays were compared to human plasma concentration time curves to establish IVIVCs. While apparent dissolution yielded poor IVIVC, both molecular dissolution and dissolution-permeation yielded good and comparable IVIVCs. Finally, a refined mechanistic understanding is derived from the aforementioned dissolution and dissolution-permeation data to explain the observed differences.

2026-01-01·TOXICOLOGY

Antiparasitic agent emodepside exerts cytotoxicity in human corneal stromal cells by blocking the interaction between mini-chromosome maintenance 6 protein (MCM6) and chromatin licensing and DNA replication factor 1 (CDT1)

Article

作者: Yin, Hao ; Gao, Hanyu ; Gao, Han

Emodepside, a novel antiparasitic agent, exhibits remarkable efficacy against nematodes. Recent research from a phase 2b clinical trial has demonstrated that the most frequent adverse event in the emodepside treatment group is blurred vision, but the mechanism of blurred vision remains largely unexplored. To provide references for secure medication and prospective therapeutic interventions of emodepside, we conducted an investigation into the cytotoxic effects of emodepside on the corneal stroma and its underlying mechanisms using an in vitro model of human corneal stromal (HCS) cells. The loading of the mini-chromosome maintenance 6 protein (MCM6) onto chromatin at replication origins by chromatin licensing and DNA replication factor 1 (CDT1) constitutes a crucial step in licensing DNA for replication. This study demonstrates that emodepside directly binds to the CDT1-binding domain (CBD) of MCM6, competitively blocking the MCM6-CDT1 interaction as confirmed by modified enzyme-linked immunosorbent assay and drug affinity responsive target stability assays. Molecular docking reveals that emodepside binds to CBD through hydrogen bonds with Lys754, Ile760, and Lys770. In HCS cells, this blockade results in the inhibition of DNA replication licensing and a decrease in DNA synthesis, as evidenced by the ethynyl-deoxyuridine incorporation assay, leading to cell cycle arrest at the G₀/G₁ phase. Moreover, emodepside-induced cell cycle arrest in HCS cells leads to dose-dependent apoptosis and proliferation inhibition with the IC₅₀ value being 32.3 μM. In conclusion, this study not only provides new insights into the mechanism of emodepside-induced vision blur but also offers a valuable molecular tool for the research of MCM6-CDT1 interaction.

2025-12-01·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of the new active ingredient tigolaner, an allosteric modulator of the GABA-gated chloride channel for use as a spot-on ectoparasiticide in animal health

Article

作者: Raming, Klaus ; Mencke, Norbert ; Turberg, Andreas ; Hallenbach, Werner ; Lösel, Peter ; Ebbinghaus-Kintscher, Ulrich ; Köbberling, Johannes ; Schwarz, Hans-Georg ; Bretschneider, Thomas ; Maue, Michael ; Neumann, Julia Hahn ; Hübsch, Walter ; Adamczewski, Martin ; Lindner, Niels ; Fischer, Reiner ; Décor, Anne ; Görgens, Ulrich ; Ilg, Kerstin ; Wölfel, Katharina

Parasiticides play a crucial role in animal health. The need for innovative ectoparasiticides for companion animals has been growing, driven by the risks posed by parasites to both animals and humans. We detail here the discovery pathway of tigolaner, an ectoparasiticide, offering up to 13 weeks protection against fleas and ticks to cats. Felpreva® employs this active ingredient for ectoparasite control together with the endoparasiticides emodepside and praziquantel. It was approved by the European Medicines Agency in November 2021. The discovery of tigolaner resulted from research at Bayer focused on finding novel molecules inhibiting GABA-gated chloride channels (GABA-Cls), with an improved toxicological profile and resistance-breaking potential when compared to dieldrin and fipronil. A high-throughput in vitro screening campaign on GABA-Cls, followed by a "mix-match" synthetic approach, led to the identification of several lead compounds acting as allosteric modulators. The GABA lead class compounds showed a different binding site when compared to fipronil. They have a unique chemotype based on a pyrazole moiety. Further variations of the central ring led to the discovery of tigolaner. Selected structure-activity relationships from the project are presented. Some synthetic pathways for tigolaner and its analogs are also described. This publication also outlines the efficacy of tigolaner against various parasites, making it a key compound of the Felpreva® product.

项与依莫赛普相关的新闻（医药）

2025-11-03

·凯美科

感染性疾病领域天然产物衍生药物的临床研发进展

前文内容，请点击以下链接: 天然产物衍生药物的临床开发与审批现状综述(2014-2025) 3. 感染性疾病领域天然产物衍生药物临床评估进展天然产物（NPs）在新一代抗感染药物的研发中始终发挥着关键作用。然而，尽管临床需求紧迫且耐药性威胁日益加剧，大型制药公司却已缩减甚至放弃了抗感染药物的开发投入。抗菌药物研发进展明显放缓，尤其针对革兰氏阴性菌（G-ve）的药物研发陷入停滞90–92，其中商业回报不足是导致这一领域萎缩的重要原因93–95。目前，抗菌药物的创新重任主要落在：中小型生物技术公司（部分公司如Achaogen、Tetraphase虽成功获批新抗生素却因收入不足而倒闭）公私合作项目及非营利性倡议与此同时，间接作用型抗菌药和生物制剂等非传统手段逐渐成为新的研发方向90,96–99，例如：直接或间接作用的噬菌体、蛋白质、微生物及单克隆抗体（mAbs）；通过毒力抑制、耐药性缓解、肠道菌群重建或增强宿主免疫力以清除感染的间接作用制剂。相比之下：抗真菌药物创新仍十分有限，近几十年来仅有少数新类别进入临床或获批49,100；抗病毒药物研发因应对SARS-CoV-2等新发病毒威胁而较为活跃，但多数成果仍局限于特定病毒，广谱抗病毒药物的需求持续存在101；抗寄生虫药物研发管线也相对薄弱，突破性疗法寥寥无几102,103。本文在第3.1节（表4）中详述处于临床试验阶段的NP与NP-D类抗菌药物，并在第3.2节（表5）中讨论抗寄生虫、抗病毒及抗真菌候选药物。表4 截至2024年12月31日处于临床试验阶段的NP和NP-D抗菌化合物（按年份排序）注释说明： a 如果抗生素类别与先导化合物不同时标注 b 同时作为抗真菌药物进行临床试验（详见第3.3节） c 结构未公开缩写词解释： ABSSSI：急性细菌性皮肤及皮肤结构感染 CABP：社区获得性细菌性肺炎 cUTI：复杂性尿路感染 PJI：假体周围关节感染 TB：结核病表5 截至2024年12月31日处于临床试验阶段的NP和NP-D抗寄生虫、抗病毒和抗真菌化合物（按年份排序）注释说明： a Q-格里菲辛为天然产物（NP），通过直接分离（I）工艺生产 b 反式藏红花素同时开展肿瘤学相关临床试验 c HRS9432由福建圣迪制药开发，江苏恒瑞医药参与 d PL-18同时具有抗菌活性研究缩写说明： NP：天然产物；NP-D：天然产物衍生物；SS：半合成；TS：全合成；I：直接分离 ARDS：急性呼吸窘迫综合征；COVID-19：2019冠状病毒病 3.1 抗菌药物那氟霉素（Nafithromycin, 3.01，WCK 4873）酮内酯类抗生素 III期临床试验完成药物类别：酮内酯类抗生素，具有广谱抗菌活性104–106。研发单位：印度Wockhardt Limited。研发进展：在印度完成一项针对社区获得性细菌性肺炎（CABP）的III期临床试验（CTRI/2019/11/021964）107。2025年1月2日（略超出本综述截止日期），Wockhardt宣布那氟霉素在印度获批用于CABP治疗108。抗菌肽药物开发（江苏普莱医药生物技术有限公司）培西加南（Peceleganan, 3.02，PL-5, V681）抗菌肽 III期临床试验完成结构特征：26聚体α螺旋抗菌肽，为天蚕素A与蜂毒肽B的杂交肽109,110。研发进展：完成一项针对皮肤伤口感染的III期临床试验（ChiCTR2100047202）111。正在开展另一项III期试验（ChiCTR2300071255）评估其伤口感染疗效。已向中国国家药品监督管理局（NMPA）提交伤口感染的上市申请。同时开展II期临床试验（NCT06189638）评估其对糖尿病足感染的治疗效果112。 PL-18（3.03）抗菌肽 Ib/II期临床试验结构特征：15聚体α螺旋抗菌肽，源自幽门螺杆菌核糖体蛋白L1（RpL1）的N端序列109,110,113。研发进展：完成一项针对细菌性阴道病（栓剂给药）的I期临床试验（NCT05340790）。目前正在进行一项Ib/II期临床试验（CTR20232467），评估其对单纯性外阴阴道念珠菌病的疗效。扎洛加南（Zaloganan, 3.04，PLG0206，WLBU2）抗菌肽 I期临床试验完成药物类别：24聚体抗菌肽（AMP），灵感来源于具有广谱抗菌活性的人源抗菌肽LL37114–117。抗菌谱：对革兰阳性菌（G+ve）、革兰阴性菌（G-ve）及生物膜均有抑制作用。研发进展：完成一项针对假体周围关节感染（PJI）的I期临床试验（NCT05137314），采用术中局部冲洗给药118。完成一项静脉给药的I期试验（ACTRN12618001920280）。CARB-X近期宣布支持开发3.04的缓释制剂，用于治疗骨折相关感染119。 HRS-8427（结构未公开）头孢菌素衍生物 III期临床试验药物类别：头孢地尔（cefiderocol, 2.23）衍生物120–122。研发单位：江苏恒瑞医药。研发进展：正在进行一项针对复杂性尿路感染（cUTI）的III期临床试验（NCT06569056）。头孢地尔（2.23，第2.1节）为一种通过整合铁载体增强细胞摄取的头孢菌素类抗生素，2019年首次获批用于cUTI治疗123,124。贝那培南（Benapenem, 3.05）碳青霉烯类 II/III期临床试验完成药物类别：静脉用碳青霉烯类抗生素，结构与厄他培南相关。研发进展：2020年5月在中国完成一项针对cUTI的II/III期临床试验（NCT04505683）125,126。上海医药集团于2021年获得授权，其2023年年报中将3.05列为在研项目127。桑费曲南酯（Sanfetrinem cilexetil, 3.06，GV-104326）三环碳青霉烯类 II期临床试验药物类别：合成三环碳青霉烯类（三环类）抗生素的前体药物128,129。研发历史：1990年代已完成针对呼吸道感染的II期临床试验，后因商业考量暂停开发130。2022年5月启动一项早期杀菌活性（EBA）II期试验（NCT05388448）131。拓展方向：目前已有其他研究关注β-内酰胺类药物在结核病治疗中的重新定位132,133。利福斯替尼唑（Rifasutenizol, 3.07，TNP-2198）杂合分子 III期临床试验完成药物类别：利福霉素-甲硝唑杂合分子134。研发单位：天恩医药（TenNor）。给药特性：口服给药，无全身性吸收。研发进展：近期完成一项III期临床试验（NCT05857163），联合雷贝拉唑和阿莫西林用于治疗幽门螺杆菌感染患者135。利法喹嗪酮（Rifaquizinone, 3.08，TNP-2092，CBR 2092）杂合分子 II期临床试验完成药物类别：利福霉素-喹啉嗪杂合分子（先导化合物ABT-719，具氟喹诺酮类特性）136–138。研发单位：天恩医药（TenNor Therapeutics）。适应症与进展：静脉给药：已完成针对革兰阳性菌急性细菌性皮肤和皮肤结构感染（ABSSSI）的II期试验（NCT03964493）。已完成针对假体周围关节感染（PJI）的II期试验（NCT04294862）。计划开展上述两适应症的III期临床试验139。口服给药：正在评估用于肝硬化肝性脑病（I/II期，NCT06135675）及腹泻型肠易激综合征（I期）的治疗。作用机制：通过杂合结构双靶点作用——RNA聚合酶（利福霉素组分）及DNA旋转酶/拓扑异构酶IV（喹啉嗪酮组分）137。乌普加南（Upleganan, 3.09，EVER206，SPR206）多粘菌素类似物 I期临床试验完成药物类别：多粘菌素类似物。研发合作：美国Spero Therapeutics 大中华区、韩国及部分东南亚地区：Everest Medicines 其他地区：辉瑞欧洲（Pfizer Europe）适应症：多重耐药革兰阴性菌感染。研发进展：已完成四项I期临床试验（NCT03792308、NCT04868292、NCT04865393、ChiCTR2200056692）140–142。计划开展II期临床试验。 MRX-8（结构未公开）多粘菌素类似物 I期临床试验完成药物类别：多粘菌素类似物，为通过极性酯键连接脂肪酸尾链形成的"软性"前体药物，水解后生成活性代谢物MRX-8039（3.14）143–145。研发单位：MicuRx。研发进展：已完成两项I期临床试验（NCT04649541、CRT20221866）147。专利US9971394中化合物34（3.15）为代表性实例146。 BRII-693（3.10，QPX-9003，F365）合成多粘菌素衍生物 I期临床试验完成药物类别：合成多粘菌素衍生物，由莫纳什大学研究人员发现148。适应症：铜绿假单胞菌和鲍曼不动杆菌感染。研发进展：Qpex制药（现为盐野义子公司）于2022年7月完成I期试验（NCT04808414）。全球开发权已授权给Brii Biosciences公司149。 ASK0912（3.11，多粘菌素S2，IMB-0912）天然多粘菌素 I期临床试验进行中药物类别：天然多粘菌素类抗生素。安全性优势：与多粘菌素B和E相比，肾细胞毒性和急性毒性较低150。临床前研究：在鲍曼不动杆菌小鼠模型中显示出良好的体内活性151。研发单位：江苏奥赛康药业。研发进展：已完成一项I期试验（CTR20222379）122,152。另一项I期试验（CTR20243311）正在进行中。齐法环素（Zifanocycline, 3.12，KBP-7072）四环素衍生物 I期临床试验完成药物类别：氨甲基环素类四环素衍生物，为蛋白质合成抑制剂，具有广谱抗菌活性153–155。研发单位：KBP BioSciences。研发进展：已完成四项I期临床试验（最近一项为NCT05507463）。 EBC-1013（3.13）非传统抗菌药 I期临床试验药物来源：为替吉拉诺替酯（tigilanol tiglate, 3.14，第7.1节）的半合成衍生物156–158。研发单位：QBiotics。适应症与进展：正在开展I期临床试验（ACTRN12624000544572），评估其促进下肢静脉溃疡伤口愈合的潜力156。为目前唯一进入临床试验阶段的非传统NP-D类抗菌药物。同步开发用于犬、马等动物的急慢性伤口管理。作用机制：作用于细菌细胞壁，导致革兰阳性菌与革兰阴性菌细胞壁通透性增加通过靶向胞外聚合物基质破坏已形成的生物膜激活免疫细胞产生活性氧（ROS）156 临床前研究：在糖尿病慢性伤口小鼠模型中，3.13可提高宿主防御肽表达、调节细胞因子水平、激活免疫细胞并加速伤口愈合156。 RG6436（GGDC-0829，结构未公开）芳基霉素衍生物 I期临床试验药物类别：芳基霉素（arylomycin）衍生物159–161。研发单位：基因泰克（罗氏）。作用靶点：芳基霉素（如arylomycin A-C16, 3.15）为链霉菌来源的SPase抑制剂162,163。SPase（信号肽酶）通过水解分泌蛋白N端信号肽，对细菌生存和毒力至关重要164–166。RG6436特异性抑制大肠杆菌I型信号肽酶LepB167。研发进展：正在开展I期临床试验（ISRCTN18049481），开发为静脉制剂用于复杂性尿路感染（cUTI）治疗。相关候选药物：另一芳基霉素LepB抑制剂RG-6319（结构未公开）已完成两项I期试验（ISRCTN15259645、ISRCTN16073754），但后续开发已中止，资源集中于RG6436168。 3.2 抗寄生虫、抗病毒及抗真菌药物依莫赛普（Emodepside, 3.16，BAY 44-4400）抗寄生虫药 II期临床试验药物类别：PF1022A的双吗啉衍生物。研发单位：被忽视疾病药物研发计划组织（DNDi）。应用背景：自2005年起与吡喹酮联用治疗猫、狗寄生性线虫感染169。临床进展：正在进行针对类圆线虫（Strongyloides stercoralis）的II期试验（NCT06373835）盘尾丝虫病的II期试验（NCT05180461）170–172 已完成针对人鞭虫（Trichuris trichiura）、钩虫（NCT05017194）及单独钩虫感染（NCT05538767）的II期试验173 母体化合物PF1022A：1992年首次从Rosellinia属真菌中报道174，对鸡蛔虫有体内活性，但对细菌、酵母及其他真菌无体外活性175–177。作用机制：主要激活SLO-1钾通道178,179 与latrophilin受体相互作用180,181 导致虫体麻痹及GABA能传递调节182 格里菲辛（Griffithsin）抗病毒蛋白 I期临床试验完成药物来源：从新西兰红藻Griffithsia sp.中分离的121个氨基酸凝集素。抗病毒谱：对HIV、2型单纯疱疹病毒及丙型肝炎病毒具有皮摩尔级抑制活性。作用机制：通过结合病毒颗粒表面高甘露糖寡糖末端的甘露糖残基，引发聚糖交联，抑制病毒入侵185,186。研发进展：路易斯维尔大学开发了鼻喷剂型（Q-格里菲辛，含M78Q突变以提高氧化稳定性）已完成两项用于COVID-19预防的I期试验（NCT05437029、NCT05122260）187 早期I期试验（NCT02875119）评估其与卡拉胶联用预防性传播感染的潜力，安全性良好188 生产优势：可通过重组表达系统生产183,184。沙比沙布林（Sabizabulin, 3.17，VERU-111，ABI-231）抗病毒/抗肿瘤 III期临床试验完成药物类别：康普瑞汀A4（combretastatin A4, 3.18）结构启发类似物189。研发单位：Veru Inc。临床进展： 2022年中完成一项针对COVID-19高危急性呼吸窘迫综合征（ARDS）患者的III期试验（NCT04842747）；中期分析显示较安慰剂组绝对死亡率降低24.9%190 后续开发将取决于资金与合作临床需求曾评估用于转移性去势抵抗性前列腺癌治疗191，但一项III期试验（NCT04844749）于2023年因战略原因中止作用机制：通过结合微管蛋白秋水仙碱位点破坏微管聚合，导致快速分裂细胞周期停滞与凋亡189 可干扰冠状病毒S蛋白分布，阻碍病毒颗粒胞内运输、组装与复制192,193 藏红花素（Transcrocetin, 3.19）抗病毒/ARDS治疗 II期临床试验完成药物来源：黄色脱辅基类胡萝卜素，源自栀子（Gardenia jasminoides）与藏红花（Crocus sativus）等植物194。生物合成：通过玉米黄质酶切及醛基还原生成195–197。临床进展： Leaf4Life开发的脂质体制剂（LEAF-4L6715）已完成COVID-19相关ARDS的I/II期试验（NCT04378920）198 一项III期试验（NCT06640777）已注册但尚未启动其钠盐制剂由Diffusion Pharmaceuticals（现属CervoMed）开展COVID-19的II期试验（NCT04573322）200，但后续开发似已中止作用机制：通过降低血浆粘度并改变水分子结构，增强氢键形成，促进氧扩散梯度下的氧输送效率194,199。 SF001（3.20，AM-2-19）抗真菌药 I期临床试验药物类别：两性霉素B的N-1,3-二羟丙基-2-酰胺衍生物201,202。研发单位：Elion Therapeutics。临床进展：正在开展静脉制剂I期试验，评估治疗侵袭性曲霉病潜力口服剂型亦在评估中安全性优势：两性霉素B的人肾毒性与其胆固醇提取作用相关；3.20通过选择性增强麦角固醇提取能力，在小鼠及人原代肾细胞中显示肾脏保护特性203–205。 HRS9432（结构未公开）抗真菌药 II期临床试验药物类别：阿尼芬净（anidulafungin）衍生物121。研发单位：福建新cadia制药。临床进展：正在开展II期试验（NCT06194201），评估治疗念珠菌血症和/或侵袭性念珠菌病。相关药物：其他棘白菌素类药物如瑞扎芬净（rezafungin, 2.35）已于2023年获批（第2节）48。 SCY-247（3.21）抗真菌药 I期临床试验启动药物类别：第二代Fungerp类抗真菌药49,206–208，为真菌来源三萜烯芬净（enfumafungin, 3.22）衍生物209。研发单位：Scynexis。临床进展：2024年12月宣布启动针对侵袭性真菌感染的I期试验（ACTRN12624001393549、ACTRN12624001392550）210。同类首创新药：伊布雷沙芬净（ibrexafungerp, 2.30）作为首个Fungerp类药物于2021年获批（第2节）47,49。待续广州凯美科信息技术有限公司是一家以化学信息学软件为核心业务的企业。公司成立于2019年10月，竭诚为国内医药、化工、食品等领域用户提供高质量的化学信息学软件解决方案和技术服务。作为加拿大ACD/Labs公司在国内的合作伙伴，我们在化合物结构鉴定、化学信息管理、色谱方法开发、化合物成药性评价、药物分子设计、分子模拟等方面累积了丰富的服务经验，并且得到广泛好评。产品包括(点击查看详情)： ✅ 化合物波谱解析系列 ✅ 化合物成药性预测 ✅ 化合物性质预测系列 ✅ 色谱方法开发系列 ✅ 实验室化学信息管理 —————————————————— ✅ 智能解析｜👉 [申请核磁/质谱解析软件演示]✅ 疑难攻坚｜📩 [提交疑难数据，获取专家支援]✅ 购买升级｜💼 [单位采购/版本更新/技术培训] 📢 联系我们：▔▔▔▔▔▔▔▔▔▔▔🧑 产品经理｜胡炽文📲 电话/微信｜18680221948📮 服务邮箱｜hcw@chemico.com.cn🌍 官网直达｜www.chemico.com.cn 扫码咨询

临床3期微生物疗法

2025-10-26

·道道之道

【本周医刊】2025年第43周医学期刊更新

2025年第43周（2025.10.19-2025.10.25）重要医学期刊论著更新如下： 1.综合期刊 LANCET 题目：Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial 翻译：伊布替尼联合利妥昔单抗对比免疫化疗治疗初治套细胞淋巴瘤患者（ENRICH研究）：一项随机、开放标签、2/3期优效性试验题目：Prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity: a WHO individual participant data meta-analysis 翻译：产后出血临床标志物预测孕产妇死亡或严重并发症的预后准确性：一项世界卫生组织（WHO）个体参与者数据荟萃分析题目：Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial 翻译：每日一次舒噻美治疗阻塞性睡眠呼吸暂停（FLOW研究）：一项多中心、随机、双盲、安慰剂对照、剂量探索2 期试验题目：Assessment of malnutrition in preschool-aged children by mid-upper arm circumference in the Gaza Strip (January, 2024–August, 2025): a longitudinal, cross-sectional, surveillance study 翻译：加沙地带通过上臂中围评估学龄前儿童营养不良状况（2024年1 月—2025年8 月）：一项纵向横断面监测研究 NEW ENGLAND JOURNAL OF MEDICINE 题目：Hypertonic Saline or Carbocisteine in Bronchiectasis 翻译：支气管扩张症中的高渗盐水或羧甲司坦题目：Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation 翻译：阿司匹林在接受口服抗凝治疗的慢性冠状动脉综合征患者中的作用题目：Common Diseases in Clinical Cohorts — Not Always What They Seem 翻译：临床队列中的常见疾病——并非总是看起来那样题目：Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis 翻译：索他西普用于诊断后第一年内的肺动脉高压题目：Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans 翻译：2024-2025 年新冠疫苗与美国退伍军人新冠病毒感染结局的关联 BMJ-BRITISH MEDICAL JOURNAL 题目：Exposure to sugar rationing in first 1000 days after conception and long term cardiovascular outcomes 翻译：受孕后前 1000 天糖配给暴露与长期心血管结局题目：Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia 翻译：抗 CD38 单克隆抗体CM313 用于原发性免疫性血小板减少症 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 题目：Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial 翻译：儿童心脏移植后使用依维莫司和低剂量他克莫司的随机临床试验题目：Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial 翻译：无症状性心房颤动的远程筛查：AMALFI 随机临床试验 NATURE MEDICINE 题目：Cardiotropic AAV gene therapy for heart failure: a phase 1 trial 翻译：心力衰竭的亲心肌腺相关病毒（AAV）基因疗法：一项1 期试验题目：Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial 翻译：SARS-CoV-2 DNA 编码的单克隆抗体在健康成年人中的安全性和药代动力学：一项1 期试验题目：Plasma proteome adaptations during feminizing gender-affirming hormone therapy 翻译：女性化性别确认激素治疗期间的血浆蛋白质组适应性变化题目：Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis 翻译：在多发性硬化症中，髓鞘损伤先于轴突损伤和症状发作题目：Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial 翻译：循环肿瘤 DNA 指导的局部晚期结肠癌辅助治疗：随机2/3 期DYNAMIC-III 试验题目：YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial 翻译：YAP/TEAD 抑制剂VT3989 用于实体瘤：一项1/2 期试验 LANCET DIGITAL HEALTH（本周无更新） NPJ DIGITAL MEDICINE 题目：Evaluating human-in-the-loop strategies for artificial intelligence-enabled translation of patient discharge instructions: a multidisciplinary analysis 翻译：评估人工智能辅助的患者出院指导翻译中人工介入策略：一项多学科分析题目：Active remote monitoring of long-term conditions with mobile devices: a systematic review of cost-effectiveness analyses 翻译：使用移动设备对长期病症进行主动远程监测：成本效益分析的系统综述题目：Real-time detection of respiratory circuit events in mechanical ventilation using deep learning 翻译：基于深度学习的机械通气中呼吸回路事件的实时检测题目：HONeYBEE: enabling scalable multimodal AI in oncology through foundation model-driven embeddings 翻译：HONeYBEE：通过基础模型驱动的嵌入在肿瘤学中实现可扩展的多模态人工智能题目：Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets 翻译：关节受累的部位和程度将类风湿关节炎分为不同的临床亚组题目：Streamlined machine learning model for early sepsis risk prediction in burn patients 翻译：用于烧伤患者早期败血症风险预测的简化机器学习模型题目：A deep learning based automatic report generator for retinal optical coherence tomography images 翻译：基于深度学习的视网膜光学相干断层扫描图像自动报告生成器 2.肿瘤学 CA-A CANCER JOURNAL FOR CLINICIANS（本周无更新） ANNALS OF ONCOLOGY 题目：Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial 翻译：曲妥珠单抗德鲁替康单药或序贯紫杉醇、曲妥珠单抗和帕妥珠单抗用于高危HER2 阳性早期乳腺癌（DESTINY-Breast11）：一项随机、开放标签、多中心的3 期试验题目：Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC 翻译：生存率提高与发病率上升：来自非小细胞肺癌脑膜转移最大规模回顾性研究的见解题目：Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy 翻译：在 SERENA-6 试验中，卡米司琼联合CDK4/6 抑制剂治疗一线内分泌治疗期间出现ESR1 突变的晚期乳腺癌患者的患者报告结局题目：The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study 翻译：非小细胞肺癌脑膜转移的演变格局：一项国际性、当代、多中心队列研究题目：Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study 翻译：Capivasertib 联合阿比特龙用于PTEN 缺陷型转移性激素敏感性前列腺癌：CAPItello-281 3 期研究 JOURNAL OF CLINICAL ONCOLOGY（本周无更新） LANCET ONCOLOGY（本周无更新） NATURE CANCER 题目：Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy 翻译：用膜结合型 SLP-76 改造T 细胞可克服CAR-T 细胞疗法对低抗原的耐药性题目：MEF2D-expressing cancer precursors reprogram tissue-resident macrophages to support liver tumorigenesis 翻译：表达 MEF2D 的癌前细胞重编程组织驻留巨噬细胞以支持肝脏肿瘤发生 JAMA ONCOLOGY（本周无更新） CANCER RESEARCH（本周无更新） CLINICAL CANCER RESEARCH（本周无更新） JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE（本周无更新） 3.内分泌学与代谢 LANCET DIABETES & ENDOCRINOLOGY（本周无更新） 4.呼吸病学 LANCET RESPIRATORY MEDICINE（本周无更新） 5.心血管病学 EUROPEAN HEART JOURNAL 题目：Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial 翻译：阿凡卡坦治疗症状轻微的梗阻性肥厚型心肌病患者的疗效：SEQUOIA-HCM试验结果题目：Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool 翻译：从单个超声心动图视频片段检测心脏淀粉样变性：一种新型的基于人工智能的筛查工具题目：Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model 翻译：恩格列净在肥厚型心肌病小鼠模型中提高代谢效率并改善左心室肥厚 CIRCULATION 题目：Ivabradine in Patients Undergoing Noncardiac Surgery: A Randomized Controlled Trial 翻译：伊伐布雷定在非心脏手术患者中的应用：一项随机对照试验题目：Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial 翻译：沙库巴曲缬沙坦与辅助乳腺癌治疗期间心脏功能障碍的预防：PRADA II 随机临床试验题目：PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux 翻译：PYGM 通过增强糖原分解和促进自噬流来预防心肌梗死 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 题目：Effect of Intensive Blood Pressure Lowering Treatment on Retinal Microvasculature: Secondary Analysis From ESPRIT 翻译：强化降压治疗对视网膜微血管的影响：ESPRIT研究的二次分析题目：Modest Effects of Intensive Blood Pressure–Lowering on Quality of Life in Patients at High Cardiovascular Risk: The ESPRIT Trial 翻译：强化降压对高心血管风险患者生活质量的适度影响：ESPRIT试验题目：Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial 翻译：强化血压控制对中风的影响：ESPRIT 试验的预先指定二次分析题目：Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial 翻译：老年高血压患者的强化血压控制：STEP 试验的6 年结果题目：Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT 翻译：使用 PREVENT 方程比较SPRINT 研究中强化与标准收缩压控制用于一级预防的效果 6.传染病学 LANCET INFECTIOUS DISEASES 题目：Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study 翻译：奥洛非芬用于治疗几乎无治疗选择或无治疗选择的侵袭性真菌病患者：一项单臂、开放标签的2b 期研究题目：Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study 翻译：智利全国呼吸道合胞病毒（RSV）免疫策略首个季节中尼塞韦单抗的有效性及影响（NIRSE-CL研究）：一项回顾性观察研究题目：Incidence of health-care-associated infections in long-term care facilities in nine European countries: a 12-month, prospective, longitudinal cohort study 翻译：欧洲 9 个国家长期护理机构中医院相关性感染的发生率：一项为期12 个月的前瞻性纵向队列研究题目：Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial 翻译：舒他唑利联合贝达喹啉、德拉马尼与莫西沙星治疗肺结核（PanACEA-SUDOCU-01研究）：一项前瞻性、开放标签、随机的2b 期剂量探索试验题目：Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial 翻译：地帕唑利联合贝达喹啉、德拉马尼与莫西沙星治疗肺结核（PanACEA-DECODE-01研究）：一项前瞻性、随机、开放标签的2b 期剂量探索试验题目：Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial 翻译：新一代 mRNA-1283 新冠疫苗与mRNA-1273 疫苗的有效性、免疫原性及安全性对比（NextCOVE研究）：一项3 期、随机、观察者设盲、活性对照试验结果题目：Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial 翻译：延长奈玛特韦 - 利托那韦治疗免疫功能低下新冠患者的疗程（EPIC-IC研究）：一项安慰剂对照、随机、双盲的2 期试验题目：Efficacy and safety of ascending doses of emodepside in comparison with ivermectin in adults infected with Strongyloides stercoralis in Laos: a phase 2a, dose-ranging, randomised, parallel-group, placebo-controlled, single-blind clinical trial 翻译：老挝地区感染粪类圆线虫的成人中，递增剂量的依莫帕米与伊维菌素的有效性及安全性对比：一项2a 期、剂量范围探索、随机、平行组、安慰剂对照、单盲临床试验 CLINICAL MICROBIOLOGY AND INFECTION 题目：Survival and quality-of-life in mucormycosis: a multicentric ambispective cohort study 翻译：毛霉菌病患者的生存率与生活质量：一项多中心双向性队列研究题目：Humoral and cellular immune responses in people living with HIV following successive COVID-19 vaccine booster doses 翻译：人类免疫缺陷病毒（HIV）感染者接种多剂新冠疫苗加强针后的体液与细胞免疫应答题目：Characterization of post-acute multi-organ sequelae following dengue infection 翻译：登革热感染后急性后期多器官后遗症的特征分析题目：Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women—a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU) 翻译：马尿酸乌洛托品用于老年女性复发性尿路感染的预防——一项三盲、随机、安慰剂对照的IV 期试验（ImpresU研究）题目：Clinical performance of a genotyping assay based on a hybrid capture technique in cervical cancer screening in China: a prospective population-based multicentre cohort study 翻译：基于杂交捕获技术的基因分型检测在中国宫颈癌筛查中的临床性能：一项基于人群的前瞻性多中心队列研究题目：Multicentre evaluation of a EUCAST-based agar-screening method for terbinafine and itraconazole susceptibility of Trichophyton spp 翻译：基于欧洲抗菌药物敏感性试验委员会（EUCAST）标准的琼脂筛查法用于毛癣菌属对特比萘芬和伊曲康唑敏感性检测的多中心评价题目：Enterobacteralesgut colonization and late-onset sepsis in neonates: a multicentre prospective study across 18 neonatal intensive care units in six countries 翻译：新生儿肠道肠杆菌目细菌定植与晚发性败血症：一项涵盖6 国18 个新生儿重症监护室的多中心前瞻性研究题目：Effectiveness of COVID-19 vaccination among dialysis and kidney transplant patients compared with matched controls—a nationwide cohort study 翻译：透析与肾移植患者新冠疫苗接种的有效性：一项与匹配对照人群对比的全国性队列研究题目：Screening and targeted prophylaxis for Clostridioides difficile infection 翻译：艰难梭菌感染的筛查与靶向预防 7.胃肠肝病学 LANCET GASTROENTEROLOGY & HEPATOLOGY（本周无更新） JOURNAL OF HEPATOLOGY（本周无更新） GASTROENTEROLOGY 题目：Barrett’s Oesophagus Surveillance Versus Endoscopy at Need Study (BOSS): A Randomized Controlled Trial 翻译：巴雷特食管监测与按需内镜检查研究（BOSS）：一项随机对照试验题目：Cost-Effectiveness of Regular Surveillance Versus Endoscopy at Need for Patients With Barrett’s Esophagus: Economic Evaluation Alongside the Barrett’s Oesophagus Surveillance Study (BOSS) Randomized Controlled Trial 翻译：巴雷特食管患者定期监测与按需内镜检查的成本效益：基于巴雷特食管监测研究（BOSS）随机对照试验的经济学评价题目：Blood-Based T-Cell Diagnosis of Celiac Disease 翻译：基于血液的 T 细胞检测诊断乳糜泻题目：Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis 翻译：胰高血糖素样肽 - 1 受体激动剂与胃肠道不良事件：一项系统评价与荟萃分析题目：An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease 翻译：炎症性肠病临床试验中糖皮质激素合理使用的国际共识 GUT 题目：Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort 翻译：高危队列中与丙型肝炎病毒再感染保护相关的抗体谱特征题目：SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL 翻译：SIRT6 通过增强GLUL 重编程谷氨酰胺代谢，从而促进肝内胆管癌发生发展题目：First genome-wide association study reveals immune-mediated aetiopathology in idiopathic achalasia 翻译：首项全基因组关联研究揭示特发性贲门失弛缓症的免疫介导发病机制题目：iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain pangenotype hepatitis E virus propagation 翻译：诱导多能干细胞（iPSC）构建的多谱系肝类器官、小肠类器官及脑类器官可支持全基因型戊型肝炎病毒增殖题目：PDE5A+cancer-associated fibroblasts enhance immune suppression in gastric cancer 翻译：表达 PDE5A 的癌相关成纤维细胞增强胃癌中的免疫抑制 HEPATOLOGY（本周无更新） CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 题目：Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study 翻译：布地奈德口崩片治疗嗜酸性食管炎长达3 年的有效性与安全性：一项开放标签扩展研究题目：Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study 翻译：布地奈德口服混悬液治疗嗜酸性食管炎的长期安全性与有效性：一项为期4 年的3 期开放标签研究题目：Endoscopic Ultrasound–Guided Portosystemic Pressure Gradient Correlates With Clinical Parameters and Liver Histology 翻译：内镜超声引导下门体静脉压力梯度与临床指标及肝脏组织学的相关性题目：Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes 翻译：采用 FIB-4 指数与FibroScan（瞬时弹性成像）的6 项国际指南对2 型糖尿病患者中代谢功能障碍相关脂肪性肝病风险分层的有效性题目：Gender-Equity Model for Liver Allocation Using Artificial Intelligence (GEMA-AI) for Waiting List Liver Transplant Prioritization 翻译：基于人工智能的性别公平肝分配模型（GEMA-AI）用于肝移植等待名单优先级排序题目：Colorectal Cancer Incidence in Steatotic Liver Disease (MASLD, MetALD, and ALD) 翻译：脂肪性肝病（代谢相关脂肪性肝病、代谢相关脂肪性肝炎、酒精性肝病）中的结直肠癌发病率题目：Association of Alcohol and Incremental Cardiometabolic Risk Factors With Liver Disease: A National Cross-sectional Study 翻译：酒精与累积性 cardiometabolic（心脏代谢）危险因素与肝病的关联：一项全国性横断面研究题目：Early Occurrence of Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt Insertion is Linked to Impaired Survival: A Multicenter Cohort Study 翻译：经颈静脉肝内门体分流术（TIPS）后早期发生肝性脑病与生存期缩短相关：一项多中心队列研究题目：Testosterone Replacement Reduces Morbidity and Mortality for Most Patients With Cirrhosis 翻译：睾酮替代治疗降低大多数肝硬化患者的发病率与死亡率题目：Ambulatory Acute Kidney Injury in Patients With Cirrhosis Is Common and Burdensome 翻译：肝硬化患者中的门诊急性肾损伤常见且危害大题目：Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease 翻译：异基因造血干细胞移植治疗单基因遗传性炎症性肠病的结局题目：Biologic Switch Timing and Risk of Infection in Patients With Ulcerative Colitis/Crohn’s Disease: A Retrospective Study 翻译：溃疡性结肠炎 / 克罗恩病患者中生物制剂转换时机与感染风险：一项回顾性研究题目：Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing Colectomy 翻译：接受托法替尼治疗的急性重症溃疡性结肠炎患者行结肠切除术后的结局题目：Cholecystectomy Is a Risk Factor for Microscopic Colitis: A Nationwide Population-based Matched Case Control Study 翻译：胆囊切除术是显微镜下结肠炎的危险因素：一项全国性基于人群的匹配病例对照研究题目：Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multicenter Study 翻译：乌帕替尼治疗克罗恩病的真实世界有效性与安全性：一项多中心研究题目：Risks of 75 Major Congenital Malformations After In Utero Exposure to Thiopurines and Anti-TNF for Maternal Inflammatory Bowel Disease 翻译：母亲患炎症性肠病时，胎儿宫内暴露于硫嘌呤类药物与抗TNF 药物后75 种主要先天性畸形的风险题目：Effect, Tolerability, and Safety of Exclusive Palatable Elemental Diet in Patients With Intestinal Microbial Overgrowth 翻译：专用适口性要素饮食治疗肠道微生物过度生长患者的疗效、耐受性与安全性题目：Simplifying Diagnosis of Bile Acid Diarrhea With Clinical and Biochemical Measurements on Blood and Single Stool Sample 翻译：通过血液与单次粪便样本的临床及生化检测简化胆汁酸性腹泻的诊断题目：Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening 翻译：结直肠癌中林奇综合征筛查的成本效益：全面生殖细胞筛查与序贯筛查对比 8.公共卫生和流行病学 LANCET PUBLIC HEALTH（本周无更新） LANCET PLANETARY HEALTH（本周无更新） LANCET GLOBAL HEALTH（本周无更新） 9.微生物学 FUNGAL DIVERSITY（本周无更新） LANCET MICROBE（本周无更新） NATURE MICROBIOLOGY 题目：Bacterial TIR-based immune systems sense phage capsids to initiate defense 翻译：细菌中基于 TIR 结构域的免疫系统通过感知噬菌体衣壳启动防御题目：Engineered Metarhizium fungi produce longifolene to attract and kill mosquitoes 翻译：工程改造的绿僵菌可产生长叶烯以吸引并杀灭蚊子题目：A widespread hydrogenase supports fermentative growth of gut bacteria in healthy people 翻译：一种广泛存在的氢化酶可支持健康人群肠道细菌的发酵生长题目：Long-read metagenomics for strain tracking after faecal microbiota transplant 翻译：长读长宏基因组学用于粪便微生物群移植后的菌株追踪题目：Activity-targeted metaproteomics uncovers rare syntrophic bacteria central to anaerobic community metabolism 翻译：活性靶向宏蛋白质组学揭示对厌氧群落代谢至关重要的稀有互营细菌 MICROBIOME 题目：Natural sex reversal imparts permanent compositional changes to the swamp eel gonadal microbiome 翻译：自然性逆转对黄鳝性腺微生物组的组成产生永久性改变题目：One Health, One Microbiome 翻译：同一健康，同一微生物组（注：“同一健康”（One Health 题目：Altered ruminal microbiome tryptophan metabolism and their derived 3-indoleacetic acid inhibit ruminal inflammation in subacute ruminal acidosis goats 翻译：亚急性瘤胃酸中毒山羊瘤胃微生物组色氨酸代谢改变及其产生的3 - 吲哚乙酸可抑制瘤胃炎症题目：Reovirus infection results in rice rhizosphere microbial community reassembly through metabolite-mediated recruitment and exclusion 翻译：呼肠孤病毒感染通过代谢物介导的招募与排斥作用，导致水稻根际微生物群落重组题目：Host miRNAs regulate Escherichia coli O157 mucosal colonization through host-mucosa-attached microbiota interactions in calves 翻译：犊牛宿主微小 RNA（miRNA）通过宿主- 黏膜附着微生物群的相互作用，调控大肠杆菌O157 的黏膜定植题目：Improving fecal transplantation precision for enhanced maturation of intestinal function in germ-free mice through microencapsulation and probiotic intervention 翻译：通过微囊包埋与益生菌干预提高粪便移植精度，促进无菌小鼠肠道功能成熟题目：Megasphaeracontributes to lactate-driven valerate production in the human gut 翻译：巨球型菌属（Megasphaera）参与人肠道中由乳酸驱动的戊酸生成题目：Silica nanoparticles suppress fungal pathogenic allies to alleviate Astragalus root rot 翻译：二氧化硅纳米颗粒通过抑制真菌病原的协同菌，缓解黄芪根腐病 10.内科学 JAMA INTERNAL MEDICINE（本周无更新） ANNALS OF INTERNAL MEDICINE 题目：Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood 翻译：儿童时期的铝吸附疫苗与慢性疾病题目：Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes 翻译：能量限制的地中海饮食及体育活动与自由进食地中海饮食在预防2 型糖尿病方面的比较题目：Effect of Personalized Risk Messages on Uptake of Colorectal Cancer Screening 翻译：个性化风险信息对结直肠癌筛查接受度的影响题目：Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis 翻译：类风湿关节炎中免疫调节药物的长期常规实验室毒性监测题目：Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets 翻译：收缩压测量误差对强化血压目标成本效益的影响题目：Geographic Variation in the Utilization of Cancer Care From Subspecialized Medical Oncologists in the United States, 2008 to 2020 翻译：2008 年至2020 年美国亚专科肿瘤内科医生提供的癌症护理利用情况的地域差 11.牙科与口腔外科 JOURNAL OF CLINICAL PERIODONTOLOGY（本周无更新）

临床结果疫苗临床2期临床1期

100 项与依莫赛普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	依莫赛普	-	DB11403

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
蛔虫病	临床3期	坦桑尼亚	Bayer AG	2025-11-25
钩虫感染	临床3期	坦桑尼亚	Bayer AG	2025-11-25
鞭虫病	临床3期	坦桑尼亚	Bayer AG	2025-11-25
类圆线虫病	临床2期	老挝	Swiss Tropical & Public Health Institute	2024-05-20
盘尾丝虫病	临床2期	美国	Bayer AG	2021-08-30
盘尾丝虫病	临床2期	美国	Drugs for Neglected Diseases initiative	2021-08-30
盘尾丝虫病	临床2期	加纳	Drugs for Neglected Diseases initiative	2021-08-30
盘尾丝虫病	临床2期	加纳	Bayer AG	2021-08-30
眼盘尾丝虫病	临床1期	德国	Bayer AG	2024-05-07
丝虫病	临床1期	英国	Bayer AG	2017-10-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05538767 (Pubmed)	临床2期	钩虫感染	293	emodepside	糧網膚積夢鏇簾齋鹹蓋(醖襯觸簾選糧繭繭獵網) = 繭構願網齋鑰艱醖夢構範廠夢選壓範繭範襯壓 (鏇鹹鬱築鏇憲築鹹繭淵 )	积极	2024-08-17
				albendazole	糧網膚積夢鏇簾齋鹹蓋(醖襯觸簾選糧繭繭獵網) = 遞構選範鬱鹽製鹹夢顧範廠夢選壓範繭範襯壓 (鏇鹹鬱築鏇憲築鹹繭淵 )
NCT05017194 (Pubmed)	临床2期	鞭虫病 \| 钩虫感染	442	Emodepside 5 mg	餘願觸鬱醖艱構壓蓋鹹(齋網選選構鏇窪網襯範) = 願製鑰窪範鹽製積顧鏇製壓蓋積鑰選鹽觸築積 (製衊夢糧獵構簾襯艱淵, 69 ~ 93)	-	2023-05-18
				Albendazole 400 mg	餘願觸鬱醖艱構壓蓋鹹(齋網選選構鏇窪網襯範) = 襯夢顧壓獵鹹糧夢齋衊製壓蓋積鑰選鹽觸築積 (製衊夢糧獵構簾襯艱淵, 6 ~ 35)
NCT03383614 (CTgov)	临床1期	丝虫病	24	EMODEPSIDE (Cohort 1: 5mg EMODEPSIDE OD)	廠鏇餘觸構夢淵獵鬱廠 = 獵遞願網齋構淵糧觸願製範構齋壓鑰簾蓋醖醖 (夢衊夢艱衊製蓋膚窪選, 憲顧淵膚繭壓積範鏇獵 ~ 繭範醖繭繭憲範蓋齋鹽) 更多	-	2020-04-15
				EMODEPSIDE (Cohort 2: 10mg EMODEPSIDE OD)	廠鏇餘觸構夢淵獵鬱廠 = 願蓋壓淵網襯膚鹹鑰齋製範構齋壓鑰簾蓋醖醖 (夢衊夢艱衊製蓋膚窪選, 壓窪積簾鑰鬱膚築鑰鏇 ~ 鬱蓋壓窪夢淵選淵齋蓋) 更多
NCT03383523 (CTgov)	临床1期	丝虫病	77	Emodepside (BAY 44-4400) (Part 1a - Treatment A)	衊憲齋廠艱夢觸獵鑰簾(壓選壓積簾鹽餘艱艱糧) = 廠艱襯衊襯繭艱構壓繭蓋鏇壓襯醖顧鏇積觸觸 (製鏇淵繭憲選鹹衊構築, 37.2) 更多	-	2020-03-09
				Emodepside (BAY 44-4400) (Part 1a - Treatment B)	衊憲齋廠艱夢觸獵鑰簾(壓選壓積簾鹽餘艱艱糧) = 範顧餘範鏇遞蓋淵齋糧蓋鏇壓襯醖顧鏇積觸觸 (製鏇淵繭憲選鹹衊構築, 19.1) 更多